Use of ibogaine for the treatment of pain

Patent metadata

Field	Value
Publication number	US-9561233-B2
Application number	US-201514635929-A
Country	US
Kind code	B2
Filing date	Mar 2, 2015
Priority date	Mar 13, 2014
Publication date	Feb 7, 2017
Grant date	Feb 7, 2017

Abstract

This invention is directed to methods of treating pain in patients comprising treating patients with ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof at a therapeutic dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL.

First claim

What is claimed is:

1. A method for treating pain in a patient, comprising administering to the patient a dosage of a compound selected from ibogaine, an ibogaine derivative, and a pharmaceutically acceptable salt and/or solvate thereof, wherein the ibogaine derivative is selected from the group consisting of coronaridine, voacangine, 18-methoxy coronaridine, 2-methoxyethyl-18-methoxycoronaridinate, 18-methylaminocoronaridine, 16-hydroxymethyl-18-hydroxyibogaline, 16-hydroxymethyl-18-methoxylibogaline, 16-ethoxycarbonyl-18-hydroxyibogaline laurate, and 16-ethoxycarbonyl-18-hydroxyibogaline methoxyethoxymethyl ether, wherein the administering provides an average serum concentration of less than about 250 ng/mL of the compound, said concentration being sufficient to alleviate and/or inhibit said pain while maintaining a QT interval of less than about 500 ms during said treatment.

2. The method of claim 1 , wherein the ibogaine, the ibogaine derivative, or the pharmaceutically acceptable salt and/or solvate thereof is administered as a single dose or multiple doses.

3. The method of claim 1 , wherein the aggregate dosage of ibogaine, the ibogaine derivative, or the pharmaceutically acceptable salt and/or solvate thereof is selected from the group consisting of from about 1.3 mg/kg to about 4 mg/kg per day, about 1.5 mg/kg to about 3 mg/kg per day, about 2 mg/kg to about 4 mg/kg per day, from about 2 mg/kg to about 3 mg/kg per day, and about 2 mg/kg per day.

4. The method of claim 1 , wherein the dosage of ibogaine, the ibogaine derivative, or the pharmaceutically acceptable salt and/or solvate thereof provides an average serum concentration of about 50 ng/mL to about 200 ng/mL.

5. The method of claim 1 , wherein the ibogaine derivative is selected from the group consisting of coronaridine, ibogamine, voacangine, 18-methoxycoronaridine, 2-Methoxyethyl-18-methoxycoronaridinate, and 18-Methylaminocoronaridine.

6. The method of claim 1 , wherein the ibogaine derivative is selected from the group consisting of 16-hydroxymethyl-18-hydroxyibogaline, 16-hydroxymethyl-18-methoxyibogaline, 16-ethoxycarbonyl-18-hydroxyibogaline laurate, and 16-ethoxycarbonyl-18-hydroxyibogaline methoxyethoxymethyl ether.

Assignees

• Demerx Inc

Inventors

• Friedhoff Lawrence

Classifications

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title

• A61K31/55 Primary

  having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title